Latest news

Terns’ new data challenges Novartis & Pfizer buys a Chinese obesity pill

Terns’ new data challenges Novartis & Pfizer buys a Chinese obesity pill

Joachim Eeckhout
Mirum's $620M acquisition of Bluejay & BioNTech’s CTLA-4 safety trade-offs

Mirum's $620M acquisition of Bluejay & BioNTech’s CTLA-4 safety trade-offs

Joachim Eeckhout
Star Therapeutics’ phase 1/2 win in bleeding disorder

Star Therapeutics’ phase 1/2 win in bleeding disorder

Joachim Eeckhout
Crescent's ADC deal with Kelun & Pharvaris' Phase 3 win in hereditary angioedema

Crescent's ADC deal with Kelun & Pharvaris' Phase 3 win in hereditary angioedema

Joachim Eeckhout
Capricor’s Duchenne comeback & Triana's $120M molecular glue degrader

Capricor’s Duchenne comeback & Triana's $120M molecular glue degrader

Joachim Eeckhout
Janux's T-cell therapy misses the mark

Janux's T-cell therapy misses the mark

Joachim Eeckhout
Belite Bio's Phase 3 success in Stargardt

Belite Bio's Phase 3 success in Stargardt

Joachim Eeckhout
Otsuka’s first FDA-approved anti-APRIL therapy & Valneva's site closure

Otsuka’s first FDA-approved anti-APRIL therapy & Valneva's site closure

Joachim Eeckhout
Daily Snap - 26. November 2025

Daily Snap - 26. November 2025

Joachim Eeckhout
Gilead invests $414M into TREX1 cancer drug from Sprint Bioscience

Gilead invests $414M into TREX1 cancer drug from Sprint Bioscience

Eduardo Longoria
Daily Snap - 25. November 2025

Daily Snap - 25. November 2025

Joachim Eeckhout
Novo Nordisk’s Alzheimer’s trials fail, casting doubt on GLP-1 drugs for neurodegeneration

Novo Nordisk’s Alzheimer’s trials fail, casting doubt on GLP-1 drugs for neurodegeneration

Eduardo Longoria
FirstBack
12345678
Next Last